Fast-acting inhalable levodopa produces positive results in clinical trial

Advances

Author: Almaz OhenePublished: 22 February 2017

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

CVT-301 Inhaler lead

Results from the phase III trial of an inhalable form of levodopa called CVT-301 are promising


A form of inhalable levodopa could be one step closer to becoming a new, fast-acting Parkinson’s treatment, after results from the phase III trial showed improvement in the motor functions of people with Parkinson’s during ‘off’ periods, according to Acorda Therapeutics.

People with Parkinson’s can experience lapses of uncontrollable and fluctuating symptoms – these are known as ‘off’ periods. The new way of ‘inhaling’ levodopa is said to deliver the drug straight to lungs, acting much faster than the current oral form that has to go through the digestive system, before reaching the brain.

Dr Peter LeWitt, director of the Parkinson’s Disease and Movement Disorders Program at the Henry Ford Hospital, Michigan, US, and lead investigator of the trial, said: “Managing symptoms of ‘off’ periods continues to be a significant unmet need for people taking oral carbidopa/levodopa regimens. Delivering levodopa by the pulmonary route offers an important treatment option for people with Parkinson’s disease.”

The Michael J Fox Foundation (MJFF) funded early work on this drug, now called CVT-301. Todd Sherer, CEO of the MJFF, said: “This potential new treatment for the management of re-emergent symptoms will address an unmet need for many patients and families.”

The clinical trial must now complete long-term safety testing in two other on-going studies.

Acorda Therapeutics plan to file a New Drug Application to the Food and Drug Administration in the US later this year, and also have plans to file a Marketing Authorisation Application in Europe by the end of 2017 – subject to additional data analysis.


Read more: App improves adherence to Parkinson’s meds

Steroid in shark livers could hold key to Parkinson’s treatment

Go Back

Share this story

Comments


  • Andy D Kemp

    This sounds promising, especially as there can often be lung difficulties pneumonia symptoms due to lower levels of Dopamine nerve transmission in that area as PD develops.

  • Susan Harris

    I can’t wait!

  • Mary Friedberg

    This is exciting news!

Related articles


Peter Dunlap-Shohl lead

Perspectives

Medical experts praise Parkinson’s graphic novel

Described as “one of the best graphic medicine books of 2016”

READ MORE
MJFF PAN merge

Global update

Fox Foundation’s new public policy unit will be “unified voice” for Parkinson’s

New merger deal to “advance key public policy priorities”

READ MORE
Copenhagen Unity Walk lead

Europe

Copenhagen carnival: campaigners and cyclists join forces for Unity Walk

Copenhagen’s streets to be overrun with Parkinson’s campaigners

READ MORE